{
  "docId": "019de075-d132-769f-97bd-4a840dd24899",
  "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 56,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "Uses a visual timeline/comparison to contrast current standard of care with the proposed product.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/23",
  "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899",
  "deckJsonHref": "/decks/019de075-d132-769f-97bd-4a840dd24899.json",
  "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.9,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "image",
      "text": "SPY001 SC comparison row",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7206d42c-6702-4a24-8045-42f862108c9b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": "Vedolizumab SC comparison row",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9f9b848-444a-42a3-b32d-f482ffb3bea6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Note: Vedolizumab SC approved in EU. US BLA resubmitted April 2023 following CRL in 2019.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4413830-de26-4b0f-a532-48d543a98ab9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "SPY001 is specifically formulated to maximize dosing without sacrificing patient comfort",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02fbe0de-a51e-47ea-9188-bd20f2923bf4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "fe42138c-85ee-48e2-a0e9-97d117b0469e",
      "evidence": "Direct visual comparison of two products across dosing and comfort metrics.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 44,
      "from": 10,
      "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}